Anatara Lifesciences (ANR) Short Interest
Anatara Lifesciences (ASX:ANR) had 0.00% of shares reported as short positions as of 14 Oct 2024, representing 558 shares. Anatara Lifesciences operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Anatara Lifesciences
Anatara Lifesciences Ltd focuses on developing non-antibiotic oral solutions targeting gastrointestinal diseases for both humans and animals. The company operates in the biotechnology sector and strives to harness novel therapeutic compositions to address significant unmet medical needs. Its strategic emphasis on non-antibiotic approaches positions it as an innovative player in the digestive health market.
Short position
Anatara Lifesciences (ASX:ANR) has 0.00% of its shares on issue reported as short positions as of 14 Oct 2024, or about 558 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.34% in May 2016. ANR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4ANR intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Anatara Lifesciences
Latest ANR news
All newsAbout
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ANR
Start a research thread or post the first pulse update